Guiding decisions throughout drug development: Localize critical PTMs at the sub-unit level

Investigating post translational modifications (PTMs) is pivotal for assessing the quality and attributes of the performance of biotherapeutics. Biotherapeutics such as monoclonal antibodies (mAb) are excellent tools for targeted treatments, however, they can be challenging to navigate due to variances in binding affinity, resistance and efficacy relating to their subunit makeup.

To examine mAbs on a subunit level and overcome these difficulties, SCIEX have formulated the Intabio ZT system which encapsulates three individual analyses to create a multidimensional data analysis system. This system is designed to enlarge subtle differences using imaged capillary isoelectric focusing (icEF) to separate molecules by their isoelectric point, which are then analyzed with ultraviolet (UV) and mass spectrometry (MS) (icEF-UV/MS).

In this presentation, now available on demand following the recent SelectScience^® Biopharma Summit 2024, Dr. Scott Mack, principal scientist at SCIEX, showcases three example mAbs they have analyzed with Intabio ZT which include Trastuzumab used in treatment of breast cancer, Infliximab for treating autoimmune conditions, and Cetuximab as the EGFR inhibitor for colorectal, head and neck cancer.